TrialDiabetes, obesity & metabolism2019

Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.

Kyu Yong Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.